Obsidian Therapeutics

10 articles with Obsidian Therapeutics

• 

  BioSpace Movers and Shakers: April 19

  4/19/2019

  Biotech, pharma and life science companies make appointments to leadership roles, with additions at Cerevance, Obsidian, KSQ, Lygos, and more.

• Obsidian Therapeutics Announces Leadership Transition and Appoints Paul K. Wotton, Ph.D., as Chief Executive Officer

  4/18/2019

  Experienced CEO brings expertise in product development, cell and gene therapies, and public biotechnology companies as Obsidian positions itself for future growth

• Obsidian Therapeutics Announces Strategic Collaboration with Celgene to Develop Novel Cell Therapies with Tunable Immunomodulatory Factors, Opening Potential for CAR-T and Other Cellular Medicines in New Settings

  1/18/2019

  Companies enter into multi-year strategic collaboration with Celgene receiving exclusive options to license cell therapies that utilize Obsidian’s Destabilizing Domain technology to modulate IL12 and CD40L activity

• 

  Weeks After $74 Billion Acquisition, Celgene Strikes Two Cancer Deals

  1/18/2019

  Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.

• Applied BioMath, LLC Announces Collaboration with Obsidian Therapeutics for Semi-Mechanistic Quantitative Modeling of a Novel Therapeutic Platform

  11/19/2018

  Applied BioMath (www.appliedbiomath.com), the industry-leader in applying mechanistic modeling to drug research and development, today announced a collaboration with Obsidian Therapeutics to provide semi-mechanistic models and analysis services.

• Obsidian Presents Preclinical Data Demonstrating Precise Regulation of Cytokines and CAR in T cells with Destabilizing Domain Technology using FDA-Approved Drugs

  11/9/2018

  Obsidian Therapeutics, a biotechnology company developing cell therapies with pharmacologic operating systems, today announced the presentation of preclinical data demonstrating fine-tuned regulation of cytokine production and CAR-T function using Destabilizing Domains (DDs) paired with FDA-approved small molecule drugs.

• Obsidian to Present Data on Regulated Cytokine Programs at the Upcoming American Society of Gene and Cell Therapy (ASGCT) 21st Annual Meeting

  5/1/2018

  Obsidian Therapeutics, Inc. announced that two abstracts highlighting preclinical data on the use of its technology for regulation of immunocytokines have been selected for presentation at the 21st Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT), taking place May 16-19, 2018, in Chicago, IL.

• Obsidian Therapeutics Presents Preclinical Data from Regulated Cytokine Programs that Enable CAR-T Therapies with Controllable Functions

  4/17/2018

  Data show ability of destabilizing domain technology platform to regulate expression of secreted and membrane-bound proteins in cell therapies

• Obsidian to Present Data on its Destabilizing Domain Technology and Product Programs at the Upcoming 2018 American Association for Cancer Research (AACR) Annual Meeting

  3/15/2018

  Obsidian Therapeutics, Inc., a biotechnology company dedicated to the development of next-generation cell and gene therapies with pharmacologic operating systems, today announced that an abstract highlighting preclinical data on its technology and therapeutic applications has been selected for presentation at the 2018 American Association for Cancer Research (AACR) Annual Meeting, taking place April 14-18, 2018 in Chicago, IL.

• Obsidian Therapeutics Presents Data Demonstrating Regulation of Protein Activity with its Next-Generation CAR-T Platform at Keystone Symposium on Emerging Cellular Therapies

  2/13/2018

  Obsidian today announced the presentation of preclinical data on its technology platform and applications at the Keystone Symposium on Emerging Cellular Therapies, to be held February 11-15, 2018 in Keystone, Colorado.